OBJECTIVE: GOG study 172 demonstrated improved progression-free (PFS) and overall (OS) survival for patients with stage III optimally debulked ovarian and peritoneal carcinoma treated with IV/IP paclitaxel and IP cisplatin compared to standard IV therapy. The inpatient administration, toxicity profile, and limited completion rate have been blamed for the lack of acceptance and widespread use of this regimen. We sought to evaluate the PFS, OS, toxicity, and completion rate of a modified outpatient IP regimen. METHODS: Using a prospectively maintained database, we evaluated the outcomes of patients who underwent primary optimal cytoreduction for stage III ovarian, tubal, or peritoneal carcinoma followed by IV/IP chemotherapy from 1/05-3/09. Our modified regimen was as follows: IV paclitaxel (135 mg/m(2)) over 3h on day 1, IP cisplatin (75 mg/m(2)) on day 2, and IP paclitaxel (60 mg/m(2)) on day 8, given every 21 days for 6 cycles. RESULTS: We identified 102 patients who initiated the modified IV/IP regimen and completed chemotherapy. The median follow-up was 43 months. The median age at diagnosis was 57 years (range, 23-76). Primary disease site was: ovary, 77 (75%); fallopian tube, 13 (13%); peritoneum, 12 (12%). FIGO stage was: IIIA, 8 (8%); IIIB, 4 (4%); IIIC, 90 (88%). Residual disease after cytoreduction was: none, 58 (57%); ≤ 1 cm, 44 (43%). The most frequent grade 3/4 toxicities were: neutropenia, 12 (12%); gastrointestinal, 8 (8%); neurologic, 6 (6%). Eighty-two (80%) of 102 patients completed 4 or more cycles of IV/IP therapy; 56 (55%) completed all 6 cycles. The median PFS and OS were 29 and 67 months, respectively. CONCLUSIONS: By modifying the GOG 172 treatment regimen, convenience, toxicity, and tolerability appear improved, with survival outcomes similar to those of GOG 172. This modified IV/IP regimen warrants further study.
OBJECTIVE:GOG study 172 demonstrated improved progression-free (PFS) and overall (OS) survival for patients with stage III optimally debulked ovarian and peritoneal carcinoma treated with IV/IP paclitaxel and IP cisplatin compared to standard IV therapy. The inpatient administration, toxicity profile, and limited completion rate have been blamed for the lack of acceptance and widespread use of this regimen. We sought to evaluate the PFS, OS, toxicity, and completion rate of a modified outpatient IP regimen. METHODS: Using a prospectively maintained database, we evaluated the outcomes of patients who underwent primary optimal cytoreduction for stage III ovarian, tubal, or peritoneal carcinoma followed by IV/IP chemotherapy from 1/05-3/09. Our modified regimen was as follows: IV paclitaxel (135 mg/m(2)) over 3h on day 1, IP cisplatin (75 mg/m(2)) on day 2, and IP paclitaxel (60 mg/m(2)) on day 8, given every 21 days for 6 cycles. RESULTS: We identified 102 patients who initiated the modified IV/IP regimen and completed chemotherapy. The median follow-up was 43 months. The median age at diagnosis was 57 years (range, 23-76). Primary disease site was: ovary, 77 (75%); fallopian tube, 13 (13%); peritoneum, 12 (12%). FIGO stage was: IIIA, 8 (8%); IIIB, 4 (4%); IIIC, 90 (88%). Residual disease after cytoreduction was: none, 58 (57%); ≤ 1 cm, 44 (43%). The most frequent grade 3/4 toxicities were: neutropenia, 12 (12%); gastrointestinal, 8 (8%); neurologic, 6 (6%). Eighty-two (80%) of 102 patients completed 4 or more cycles of IV/IP therapy; 56 (55%) completed all 6 cycles. The median PFS and OS were 29 and 67 months, respectively. CONCLUSIONS: By modifying the GOG 172 treatment regimen, convenience, toxicity, and tolerability appear improved, with survival outcomes similar to those of GOG 172. This modified IV/IP regimen warrants further study.
Authors: Rudy S Suidan; Qin Zhou; Alexia Iasonos; Roisin E O'Cearbhaill; Dennis S Chi; Kara C Long Roche; Edward J Tanner; John Denesopolis; Richard R Barakat; Oliver Zivanovic Journal: Int J Gynecol Cancer Date: 2015-05 Impact factor: 3.437
Authors: Stephen K Williamson; Gary A Johnson; Holly A Maulhardt; Kathleen M Moore; D S McMeekin; Thomas K Schulz; Gregory A Reed; Katherine F Roby; Christine B Mackay; Holly J Smith; Scott J Weir; Jo A Wick; Maurie Markman; Gere S diZerega; Michael J Baltezor; Jahna Espinosa; Charles J Decedue Journal: Cancer Chemother Pharmacol Date: 2015-04-23 Impact factor: 3.333
Authors: Vasileios D Sioulas; Maria B Schiavone; David Kadouri; Oliver Zivanovic; Kara Long Roche; Roisin O'Cearbhaill; Nadeem R Abu-Rustum; Douglas A Levine; Yukio Sonoda; Ginger J Gardner; Mario M Leitao; Dennis S Chi Journal: Gynecol Oncol Date: 2017-02-21 Impact factor: 5.482
Authors: Jennifer J Mueller; Amelia Kelly; Qin Zhou; Alexia Iasonos; Kara Long Roche; Yukio Sonoda; Roisin E O'Cearbhaill; Oliver Zivanovic; Dennis S Chi; Ginger J Gardner Journal: Gynecol Oncol Date: 2016-09-28 Impact factor: 5.482
Authors: Brooke A Schlappe; Jennifer J Mueller; Oliver Zivanovic; Ginger J Gardner; Kara Long Roche; Yukio Sonoda; Dennis S Chi; Roisin E O'Cearbhaill Journal: Gynecol Oncol Date: 2016-05-21 Impact factor: 5.482
Authors: Alexi A Wright; Angel Cronin; Dana E Milne; Michael A Bookman; Robert A Burger; David E Cohn; Mihaela C Cristea; Jennifer J Griggs; Nancy L Keating; Charles F Levenback; Gina Mantia-Smaldone; Ursula A Matulonis; Larissa A Meyer; Joyce C Niland; Jane C Weeks; David M O'Malley Journal: J Clin Oncol Date: 2015-08-03 Impact factor: 44.544
Authors: Karen A Cadoo; Rachel N Grisham; Roisin E O'Cearbhaill; Nicole N Boucicaut; Melissa Henson; Alexia Iasonos; Qin Zhou; Debra M Sarasohn; Jacqueline Gallagher; Sara Kravetz; Dmitriy Zamarin; Vicky Makker; Paul J Sabbatini; William P Tew; Carol Aghajanian; Jason A Konner Journal: Gynecol Oncol Date: 2020-01-17 Impact factor: 5.482